Nectar Lifesciences Ltd. | Small-cap | Healthcare
₹22.38
6.12%
| Nectar Lifesciences Stock Comparison:
No comparison data available
Overview Income Statement Balance Sheet Cash Flow Key Ratios

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 16.8B
Gross Profit 3.0B 17.65%
Operating Income 923.8M 5.49%
Net Income 50.0M 0.30%
EPS (Diluted) ₹0.22

Balance Sheet Metrics

Total Assets 21.9B
Total Liabilities 11.2B
Shareholders Equity 10.7B
Debt to Equity 1.05

Cash Flow Metrics

Operating Cash Flow 1.6B
Free Cash Flow 2.0B

Revenue & Profitability Trend

Nectar Lifesciences Income Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Revenue 16.8B 15.2B 16.7B 15.4B 23.7B
Cost of Goods Sold 13.9B 13.3B 13.7B 12.9B 20.0B
Gross Profit 3.0B 1.9B 3.0B 2.6B 3.7B
Operating Expenses 590.9M 596.4M 644.8M 612.3M 662.4M
Operating Income 923.8M -51.8M 1.0B 620.1M 1.6B
Pre-tax Income 182.7M -424.2M 340.8M -847.7M 374.7M
Income Tax 132.7M -182.4M 90.3M -115.0M 56.8M
Net Income 50.0M -241.8M 250.5M -732.6M 317.9M
EPS (Diluted) ₹0.22 -₹1.08 ₹1.12 -₹3.27 ₹1.42

Income Statement Trend

Nectar Lifesciences Balance Sheet From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Assets
Current Assets 12.8B 12.3B 13.5B 12.4B 16.2B
Non-Current Assets 9.1B 9.6B 10.4B 11.5B 10.2B
Total Assets 21.9B 21.9B 23.9B 23.9B 26.3B
Liabilities
Current Liabilities 9.7B 8.9B 10.0B 11.9B 12.5B
Non-Current Liabilities 1.5B 2.3B 3.0B 1.4B 2.5B
Total Liabilities 11.2B 11.2B 13.0B 13.3B 15.0B
Equity
Total Shareholders Equity 10.7B 10.6B 10.9B 10.6B 11.4B

Balance Sheet Composition

Nectar Lifesciences Cash Flow Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income 182.7M -424.2M 340.8M -594.5M 374.7M
Operating Cash Flow 1.6B 1.1B 472.9M -155.6M 2.3B
Investing Activities
Capital Expenditures -294.2M 497.3M 147.6M -310.6M -362.4M
Investing Cash Flow -294.2M 497.3M 147.6M -313.1M -358.3M
Financing Activities
Dividends Paid - - - -11.2M -13.5M
Financing Cash Flow -466.9M -408.6M -2.0B 911.7M -176.1M
Free Cash Flow 2.0B 1.0B 700.4M -98.6M 2.3B

Cash Flow Trend

Nectar Lifesciences Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 27.63
Forward P/E 6.98
Price to Book 0.43
Price to Sales 0.28
PEG Ratio 6.98

Profitability Ratios

Profit Margin 1.01%
Operating Margin 6.40%
Return on Equity 0.47%
Return on Assets 0.23%

Financial Health

Current Ratio 1.31
Debt to Equity 58.37
Beta 0.66

Per Share Data

EPS (TTM) ₹0.75
Book Value per Share ₹48.13
Revenue per Share ₹73.83

Financial data is updated regularly. All figures are in the company's reporting currency.